腹腔热灌注化疗治疗胃癌的研究现状

Current status of hyperthermic intraperitoneal chemotherapy in gastric cancer patients

关键词:  腹腔热灌注化疗  胃癌  腹膜转移

Key words:  hyperthermic intraperitoneal chemotherapy  gastric cancer  peritoneal metastasis

摘要:

胃癌患者预后差的主要原因是腹膜转移，既往的姑息性手术及全身化疗治疗模式对其疗效差。近年来腹腔热灌注化疗（hyperthermic intraperitoneal chemotherapy，HIPEC）以及围绕其开展的综合治疗模式的临床研究不断进行，证实HIPEC不仅可以预防胃癌根治术后腹膜转移，还可改善部分腹膜转移患者的生活质量，延长生存期。本文从作用机制、药物选择、治疗模式及疗效评价、预后相关生物标记物等方面对HIPEC治疗胃癌的现状进行综述。

Abstract:

The main reason of poor prognosis in gastric cancer patients is peritoneal metastasis. The effectiveness of traditional treatment modality, including systematic chemotherapy and/or palliative surgery, is disappointing due to the poor survival rate and quality of life. In recently years, clinical studies of hyperthermic intraperitoneal chemotherapy (HIPEC) and comprehensive treatment model centering HIPEC have been carried out continuously. It has been confirmed that HIPEC can not only prevent peritoneal metastasis after radical resection of gastric cancer, but also improve both the survival and the quality of life in selected patients with peritoneal metastasis. This article reviews the current status of HIPEC in gastric cancer from the aspects of mechanism, drug selection, treatment model and efficacy evaluation and prognosis related biomarkers.